Bilateral Subretinal Fluid Accumulation during Erdafitinib Therapy

Fibroblast growth factor receptor (FGFR) plays a major role in maintaining retinal pigment epithelium cells. Drugs that inhibit the FGFR pathway block the activation of the mitogen-activated protein kinase pathway, leading to the synthesis of antiapoptotic proteins and secondary subretinal fluid acc...

Full description

Saved in:
Bibliographic Details
Published in:TNOA Journal of Ophthalmic Science and Research 2024-07, Vol.62 (3), p.368-370
Main Authors: Singh, Rajneesh, Bagrecha, Nipun, Pandey, Suresh K, Chabblani, Deepesh
Format: Article
Language:English
Subjects:
central serous chorioretinopathy
erdafitinib
fgfr
Fibroblast growth factors
mitogen-activated protein kinase
mitogen-activated protein kinase inhibitor-associated retinopathy
Mitogens
Protein kinases
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fibroblast growth factor receptor (FGFR) plays a major role in maintaining retinal pigment epithelium cells. Drugs that inhibit the FGFR pathway block the activation of the mitogen-activated protein kinase pathway, leading to the synthesis of antiapoptotic proteins and secondary subretinal fluid accumulation. Erdafitinib, a potent tyrosine kinase inhibitor of fibroblast growth factor receptors (FGFRs) is one such antitumour drug that has shown significant efficacy in patients with urothelial carcinoma with FGFR alterations. We present a case report demonstrating the bilateral subretinal fluid accumulation due to erdafitinib.
ISSN:2589-4528
2589-4528
DOI:10.4103/tjosr.tjosr_50_24